Keresés eredménye

Típusa:
összetett keresés
Keresési paraméterek:
Jose F. Leis, MD, PhD | szakcikk |

<< < 1 > >>
1 találat 1 oldalon - ebből zárolt tartalom 1 db

A zárolt tartalmakat csak bejelentkezett felhasználók tekinthetik meg!

33 Ibrutinib and Rituximab Provides Superior Clinical Outcome Compared to FCR in Younger Patients with Chronic Lymphocytic Leukemia (CLL): Extended Follow-up from the E1912 Trial

Szerző: Tait D. Shanafelt, MD1 Victoria Wang2 Neil E. Kay, MD3 Curtis A. Hanson, MD4 Susan M. O'Brien, MD5 Jacqueline C. Barrientos, MD, MS6 Diane F Jelinek, PhD7 Esteban Braggio, Ph.D.8 Jose F. Leis, MD, PhD9 Cong Christine Zhang10 Steven Coutre, MD11 Paul M. Barr, MD12 Amanda F Cashen, MD13 Anthony R. Mato, MD MSCE14 Avina Singh, MD15 Michael P. Mullane, MD16 Richard F. Little, MD, MPH17 Harry P. Erba, MD, PhD18 Richard M. Stone, MD19 Mark Litzow, MD20 Martin S. Tallman, MD21
1Stanford University, Stanford, CA
2Harvard, Boston, MA
3Division of Hematology, Mayo Clinic, Rochester, MN
4Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN
5Chao Family Comprehensive Cancer Center, Division of Hematology / Oncology, Department of Medicine, University of California Irvine Health, Orange, CA
6Department of Medicine, Zucker School of Medicine at Hofstra/Northwell, Lake Success, NY
7College of Medicine, Mayo Clinic, Scottsdale, AZ
8Division of Hematology/Oncology, Mayo Clinic, Scottsdale, AZ
9Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ
10Kaiser Permanente, Fresno, CA
11Stanford Univ. School of Med., Stanford, CA
12Division of Hematology/Oncology, Wilmot Cancer Institute, University of Rochester, Rochester, NY
13Department of Medicine, Washington Univ. School of Med., Saint Louis, MO
14Center for CLL, Memorial Sloan-Kettering Cancer Center, New York, NY; CLL Program, Leukemia Service, Hematologic Malignancies Division, Memorial Sloan Kettering Cancer Center, New York, NY
15Minnesota Oncology, Burnsville, MN
16Aurora Cancer Care-Racine, Racine, WI
17National Cancer Institute, Washington; Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD; National Institutes of Health National Cancer Institute, Bethesda, MD
18University of Alabama at Birmingham, Birmingham, AL
19Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
20Division of Hematology, Mayo Clinic, Rochester, MN
21Memorial Sloan Kettering Cancer Center, New York, NY

BACKGROUND:Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab (FCR) has been the standard therapy for younger patients with CLL. FCR therapy is particularly effective in patients with immunoglobulin heavy chain variable region (IGHV) mutated CLL. Approximately half of IGHV mutated patients are progression free 8 years after FCR therapy. At the ASH 2018 meeting, we reported the initial results of the ECOG 1912 (E1912) trial, a ...


<< < 1 > >>
1 találat 1 oldalon - ebből zárolt tartalom 1 db

A zárolt tartalmakat csak bejelentkezett felhasználók tekinthetik meg!